Expert Ratings for Privia Health Group
Analysts have provided the following ratings for Privia Health Group (NASDAQ:PRVA) within the last quarter:
Where Privia Health Group Stands With Analysts
Within the last quarter, Privia Health Group (NASDAQ:PRVA) has observed the following analyst ratings:
Canaccord Genuity Maintains Buy on Privia Health Group, Lowers Price Target to $44
Canaccord Genuity analyst Richard Close maintains Privia Health Group (NASDAQ:PRVA) with a Buy and lowers the price target from $50 to $44.
50 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Indonesia Energy Corporation Limited (NYSE: INDO) jumped 75.2% to $7.87.
Imperial Petroleum Inc. (NASDAQ: IMPP) rose 52.9% to $0.7500 after declining around 7% on Friday.
Cowen & Co. Upgrades Privia Health Group to Outperform, Announces $35 Price Target
Cowen & Co. analyst Gary Taylor upgrades Privia Health Group (NASDAQ:PRVA) from Market Perform to Outperform and announces $35 price target.
Privia Health Partner Javara Reports Launch Of Opportunity For Adults 60+ In 3 Cities In Georgia, Maryland And Texas To Participate In A Trial For Investigational Vaccine Aimed At Protection From Respiratory Syncytial Virus
Adults Age 60 and Older in Georgia, Maryland and Texas Encouraged to Join Clinical Trial for RSV Prevention Vaccine
WINSTON-SALEM, N.C., Feb. 14, 2022 /PRNewswire/ -- Javara, a leading Integrated Research
56 Biggest Movers From Friday
Gainers
Hour Loop, Inc. (NASDAQ: HOUR) shares jumped 99.8% to $7.99 after the company priced its IPO at $4 per share.
SVB Leerink Maintains Outperform on Privia Health Group, Raises Price Target to $43
SVB Leerink analyst Whit Mayo maintains Privia Health Group (NASDAQ:PRVA) with a Outperform and raises the price target from $42 to $43.
SVB Leerink Maintains Outperform on Privia Health Group, Raises Price Target to $42
SVB Leerink analyst Whit Mayo maintains Privia Health Group (NASDAQ:PRVA) with a Outperform and raises the price target from $35 to $42.